Forecast
The analysts' average price target is €19.50 (+60.36%). The median is €18.23 (+49.92%).
| Buy |
Â
31 |
| Hold |
Â
18 |
| Sell |
Â
6 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Sarepta presents pipeline data and expects gradual recovery for ELEVIDYS
At the Morgan Stanley Healthcare Conference, Sarepta emphasized that marketed products generate cash flow while the siRNA pipeline supports long‑term growth. CEO Michael Severino noted early signs of stabilization after the safety‑related issues with ELEVIDYS, but expects meaningful commercial improvement only in 2027. Key near‑term catalysts are data from the multiple‑ascending‑dose studies of SRP‑1001 (FSHD) and SRP‑1003 (DM1) in the second half of 2026 and higher dose cohorts in early 2027; the PMO franchise remains robust with high treatment adherence. » More on de.investing.com
Sarepta Therapeutics appoints Michael Severino as CEO – shares rise in premarket trading
Sarepta Therapeutics named Dr. Michael Severino as its new CEO effective July 28, 2026; Doug Ingram is stepping down and will remain in an advisory role through the end of 2026. The stock rose about 5.2% in premarket trading, driven by confidence in Severino’s experience at Tessera Therapeutics and AbbVie. Analysts warn of a challenging competitive landscape in Duchenne muscular dystrophy; attention also turns to the expected Q2 results on August 5. The share price was $16.49, well below the 52-week high of $25.32 but recovered from a low of $11.68. » More on de.investing.com
Sarepta Therapeutics rises after FDA acceptance of sNDA for AMONDYS 45 and VYONDYS 53
The FDA has accepted the supplemental new drug applications (sNDAs) for AMONDYS 45 (Casimersen) and VYONDYS 53 (Golodirsen) for review and set a PDUFA date of February 28, 2027. The filings rely on the phase-3 ESSENCE study, which did not meet its primary endpoint but showed numerical trends and post‑hoc analyses favoring treatment. The news triggered a share gain of about 6.1% and was supported by Mizuho’s maintained 'Outperform' rating with a $31 price target and a favorable market backdrop. Full approval would remove substantial regulatory uncertainty for the PMO portfolio; the PMO franchise reported net product revenue of $228.6 million in Q1 2026. » More on de.investing.com
Sarepta Therapeutics stock falls after steep drop in Elevidys sales
Sarepta Therapeutics reported first-quarter Elevidys sales of $102 million versus $375 million in the year-ago quarter, driven by a restricted approval for ambulatory patients following FDA safety reviews. Total revenue was $730.8 million, down $14.1 million, partly offset by higher collaboration revenue. The stock fell about 10.3% in premarket trading to $122.96. » More on de.investing.com
Sarepta returns to profitability in Q1 2026 despite commercial realignment
Sarepta reported a non-GAAP earnings per share of $3.16 for Q1 2026 on revenue of $731 million, significantly beating expectations. The company swung to operating profitability thanks to disciplined cost management and a favorable revenue mix, with collaboration revenues (including $325 million from Roche) making up a large portion of results. ELEVIDYS generated $102 million in sales, PMO products contributed $229 million, and cash and cash equivalents stood at $748 million. Sarepta reaffirmed its 2026 guidance (net product revenue $1.2–1.4 billion) and emphasized that pipeline progress and balance-sheet developments make external capital unnecessary for the time being. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2022, Sarepta Therapeutics has already paid €0.26 in dividends. The last payout was in March 2022.
Financials
In the last quarter, Sarepta Therapeutics had revenue of €336.68m and net profit of -€25.13m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 336.68m | 1.07% |
| Gross profit | 170.25m | 19.63% |
| Net profit | -25.13m | 83.61% |
| EBITDA | 1.54m | 101.08% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.3bn |
Number of shares | 107.24m |
52-week high/low | €22.49 - €12.08 |
| Dividends | No |
Beta | 0.21 |
P/E ratio | 148.11 |
PEG ratio | 0.30 |
P/B ratio | 0.92 |
P/S ratio | 0.73 |
Company profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Name | Sarepta Therapeutics |
| CEO | Michael E. Severino |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 04/06/1997 |
| Employees | 835 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SRPT |
London Stock Exchange | 0L35.L |
Frankfurt | AB3A.F |
DĂĽsseldorf | AB3A.DU |
London | 0L35.L |
SIX | AB3A.SW |
MĂĽnchen | AB3A.MU |
Hamburg | AB3A.HM |
Milan | 1SRPT.MI |